EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy
dc.contributor.author | Fanti, Stefano | |
dc.contributor.author | Brigantii, Alberto | |
dc.contributor.author | Emmett, Louise | |
dc.contributor.author | Fizazi , Karim | |
dc.contributor.author | Gillessen, Silke | |
dc.contributor.author | Goffin, Karolien | |
dc.contributor.author | Hadaschik, Boris A | |
dc.contributor.author | Herrmann, Ken | |
dc.contributor.author | Kunikowska, Jolanta | |
dc.contributor.author | Maurer, Tobias | |
dc.contributor.author | MacLennan, Steven | |
dc.contributor.author | Mottet, Nicolas | |
dc.contributor.author | Murphy, Declan G | |
dc.contributor.author | Oprea-Lager, Daniela E. | |
dc.contributor.author | O’Sullivan, Joe M | |
dc.contributor.author | Oyen, Wim JG | |
dc.contributor.author | Rouvière, Olivier | |
dc.contributor.author | Sartor, Oliver | |
dc.contributor.author | Stenzl, Arnulf | |
dc.contributor.author | Van Poppel, Hendrik | |
dc.contributor.author | Walz, Jochen | |
dc.contributor.author | Witjes, Wim | |
dc.contributor.author | Bjartell, Anders | |
dc.date.accessioned | 2023-02-16T11:45:01Z | |
dc.date.available | 2023-02-16T11:45:01Z | |
dc.date.issued | 2022-10-01 | |
dc.identifier.citation | Fanti , S , Brigantii , A , Emmett , L , Fizazi , K , Gillessen , S , Goffin , K , Hadaschik , B A , Herrmann , K , Kunikowska , J , Maurer , T , MacLennan , S , Mottet , N , Murphy , D G , Oprea-Lager , D E , O’Sullivan , J M , Oyen , W JG , Rouvière , O , Sartor , O , Stenzl , A , Van Poppel , H , Walz , J , Witjes , W & Bjartell , A 2022 , ' EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy ' , European Urology Oncology , vol. 5 , no. 5 , pp. 530-536 . https://doi.org/10.1016/j.euo.2022.05.003 | en |
dc.identifier.issn | 2588-9311 | |
dc.identifier.other | PURE: 215607276 | |
dc.identifier.other | PURE UUID: 544f695a-1b17-4420-bc9d-b6ec3dce30f1 | |
dc.identifier.other | ORCID: /0000-0002-2691-8421/work/114480386 | |
dc.identifier.other | Scopus: 85139488755 | |
dc.identifier.other | PubMed: 35697600 | |
dc.identifier.uri | https://hdl.handle.net/2164/20070 | |
dc.description | Funding support and role of sponsor: The EAU/EANM PSMA-based imaging and therapy consensus meeting was supported by an unrestricted educational grant from Novartis; Novartis had no influence over the content of the meeting or the publication. Medical writing support was funded by the European Association of Urology Research Foundation. Acknowledgements: The authors acknowledge Emily Spieker (Management Assistant, European Association of Urology) for project management. Medical writing support was provided by Angela Corstorphine of Kstorfin Medical Communications (KMC) limited. | en |
dc.format.extent | 7 | |
dc.language.iso | eng | |
dc.relation.ispartof | European Urology Oncology | en |
dc.rights | ©2022. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/ | en |
dc.rights | This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). | en |
dc.subject | SDG 3 - Good Health and Well-being | en |
dc.subject | Computed tomography | en |
dc.subject | Consensus | en |
dc.subject | Diagnosis | en |
dc.subject | Lutetium | en |
dc.subject | Patient selection | en |
dc.subject | Positron emission tomography | en |
dc.subject | Prostate cancer | en |
dc.subject | PSMA | en |
dc.subject | Radioactive tracer | en |
dc.subject | Therapy | en |
dc.subject | Prostate-specific membrane antigen | en |
dc.subject | R Medicine | en |
dc.subject.lcc | R | en |
dc.title | EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy | en |
dc.type | Journal article | en |
dc.contributor.institution | University of Aberdeen.Other Applied Health Sciences | en |
dc.contributor.institution | University of Aberdeen.Academic Urology Unit | en |
dc.contributor.institution | University of Aberdeen.Institute of Applied Health Sciences | en |
dc.description.status | Peer reviewed | en |
dc.description.version | Postprint | en |
dc.description.version | Publisher PDF | en |
dc.identifier.doi | https://doi.org/10.1016/j.euo.2022.05.003 | |
dc.identifier.url | http://www.scopus.com/inward/record.url?scp=85139488755&partnerID=8YFLogxK | en |
dc.identifier.vol | 5 | en |
dc.identifier.iss | 5 | en |